%0 Journal Article
%A López Millán, Belén
%A Costales, Paula
%A Gutiérrez Agüera, Francisco
%A Díaz de la Guardia, Rafael
%A Roca Ho, Heleia
%A Vinyoles, Meritxell
%A Rubio Gayarre, Alba
%A Safi, Rémi
%A Castaño, Julio
%A Romecín, Paola Alejandra
%A Ramirez Orellana, Manuel
%A Anguita Mandly, Eduardo Luis
%A Jeremías, Irmela
%A Zamora, Lurdes
%A Rodríguez Manzaneque, Juan Carlos
%A Bueno, Clara
%A Morís, Francisco
%A Menéndez, Pablo
%T The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
%D 2022
%@ 2072-6694
%U https://hdl.handle.net/20.500.14352/71621
%X Patients with AML harboring constitutively active mutations in the FLT3 receptor generally have a poor prognosis (FLT3-ITDMUT). Despite the fact that several FLT3 inhibitors have been developed, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITDMUT. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin (a well-known FLT3 inhibitor). Our in vitro and in vivo experiments showed that EC-70124 exerts a robust and specific antileukemia activity against FLT3-ITDMUT AML cells while sparing healthy hematopoietic cells. Collectively, EC-70124 is a promising and safe agent for the treatment of this aggressive type of AML.
%~